Any current/future new fundraising through debt or equity?

The transcript does not mention any current or future fundraising plans through debt or equity. The discussion primarily focuses on business growth, revenue, margin guidance, capacity expansion, and market penetration. Capex plans include Rs. 2.9 Crores for renovation, Rs. 8 Crores for R&D, and Rs. 8 Crores for expansion and modernization, funded through internal accruals or existing resources (not explicitly stated). No details about raising funds via debt or equity were provided during this call.

Future growth expectations in sales/revenue/volumes?

The company expects to maintain the same topline growth and bottomline. Business is growing phenomenally at 30% to 40% year-on-year. Revenue for the current financial year is projected to cross Rs. 50 Crores. Growth drivers include high-quality production, good pricing, and marketing strategies. New product introductions from the operational R&D center will further boost growth. Expansion into international markets like the US, Brazil, Russia, and Saudi Arabia is a major focus. Export business is set to improve with new registrations and US FDA approvals. Increased digital marketing activities

Future growth expectations in earnings/operating earnings/profits/EPS?

Prevest DenPro aims to maintain strong topline growth and sustain the high EBITDA margin of around 40%, driven by specialized, value-added dental products with good pricing power. Revenue for FY2023 is expected to exceed Rs. 50 Crores with sustained profitability. The company plans robust international expansion, targeting entry into high-potential markets like the US, Brazil, and Russia, complementing existing exports to 85 countries. New capacity expansions and modernization are underway to meet growing demand efficiently. Operating margins are considered sustainable and expected to improve

Current/ Expected Orderbook/ Pending Orders?

The current order book of Prevest DenPro Limited is described as very comfortable with sufficient orders at present. The company is confident about continuing its growth without any disruption in the order inflow. There is no indication of lumpiness or delays in advanced payments from European countries despite economic instability, as payments are received on 100% advance basis. Saudi Arabian market is growing well with very good quantity of product orders, and the company expects much better business growth there in the coming times. The company is proactively expanding in international mark

Prevest DenproQ1 FY23Healthcare Equipment & Supplies

Prevest Denpro Q1 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹405P/E: 21.6Market Cap: ₹486 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company expects to maintain the same topline growth and bottomline.
Business is growing phenomenally at 30% to 40% year-on-year.
Revenue for the current financial year is projected to cross Rs. 50 Crores.
Growth drivers include high-quality production, good pricing, and marketing strategies.
New product introductions from the operational R&D center will further boost growth.
Expansion into international markets like the US, Brazil, Russia, and Saudi Arabia is a major focus.
Export business is set to improve with new registrations and US FDA approvals.
Increased digital marketing activities aim to connect with more dentists globally.
Modernization and capacity expansion of manufacturing facilities support higher production volumes.
The company is optimistic about sustained growth fueled by high-value specialized dental products.

Margin guidance

Category 3

Prevest DenPro aims to maintain strong topline growth and sustain the high EBITDA margin of around 40%, driven by specialized, value-added dental products with good pricing power.
Revenue for FY2023 is expected to exceed Rs. 50 Crores with sustained profitability.
The company plans robust international expansion, targeting entry into high-potential markets like the US, Brazil, and Russia, complementing existing exports to 85 countries.
New capacity expansions and modernization are underway to meet growing demand efficiently.
Operating margins are considered sustainable and expected to improve with market diversification, including entry into markets with better margin profiles, like the US.
R&D investments and launch of new product lines (disinfectant, oral hygiene, biomaterials) are expected to fuel growth.
Quarterly accounting changes in employee costs may normalize expense recognition, improving clarity in future earnings.
Overall, management is confident of continued double-digit growth in earnings and profits supported by strong fundamentals and business durability.

See what Prevest Denpro management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or future fundraising plans through debt or equity.
The discussion primarily focuses on business growth, revenue, margin guidance, capacity expansion, and market penetration.
Capex plans include Rs. 2.9 Crores for renovation, Rs. 8 Crores for R&D, and Rs. 8 Crores for expansion and modernization, funded through internal accruals or existing resources (not explicitly stated).
No details about raising funds via debt or equity were provided during this call.

Order book

Yes

The current order book of Prevest DenPro Limited is described as very comfortable with sufficient orders at present.
The company is confident about continuing its growth without any disruption in the order inflow.
There is no indication of lumpiness or delays in advanced payments from European countries despite economic instability, as payments are received on 100% advance basis.
Saudi Arabian market is growing well with very good quantity of product orders, and the company expects much better business growth there in the coming times.
The company is proactively expanding in international markets like US, Brazil, and Russia, and is engaging with potential buyers, suggesting a growing order pipeline.
Overall, the business prospects and order inflow are stable and strong, supporting the company’s growth trajectory.

See what Prevest Denpro management said on order book — free account, 30 seconds.

Capex plans

Yes

- Proposed capex for the financial year includes: - Rs. 2.9 Crores for renovation of existing plant and machinery. - Rs. 8 Crores for R&D facilities. - Rs. 8 Crores for expansion projects and modernization. - R&D center expected to be operational by Q2 FY2023. - New facilities for manufacturing disinfectant oral hygiene products, oral care products, and biomaterials are under advanced implementation, projected to be fully operational by Q3 FY2023, subject to regulatory approvals. - Modernization efforts ongoing with new high-speed machines installed, streamlining production and increasing capacity to cater to market demand over the next five years. - Total expanded capex made so far amounts to Rs. 11.04 Crores. - Additional modernization expenditure of around Rs. 1 Crore already spent, with another Rs. 1 Crore planned for upcoming months. Overall, key investments focus on capacity expansion, product innovation, and modernization to support growth.

Track Prevest Denpro — get its next earnings analysis in your feed

How does Prevest Denpro rank vs peers in Healthcare Equipment & Supplies?

Pro feature

ThisPrevest Denpro

Rev 2Mar 3

See where Prevest Denpro sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

How does Prevest Denpro rank in Healthcare Equipment & Supplies?

Compare Prevest Denpro against every Healthcare Equipment & Supplies company (Q1 FY23) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

What Prevest Denpro's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

Aprameya Enginee (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
QMS Medical Allied Services Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹37.3 crore . Key investor presentation takeaways from QMS Medical Allied Services Ltd's Q3 FY26 investor presentation — and how
Vaidya Sane (Q4 FY26)
170-180 crores driven by higher patient additions, increased hospital utilization, and franchise clinic growth. Key concall takeaways from Vaidya Sane Ayurved…
Avience Biomedicals Ltd (Q1 FY27)
New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…

Compare:vs Molbio Diagnosti vs Poly Medicure Ltd vs Laxmi Dental Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →